Phase 3 N=77 A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables — 24; 6; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=27 Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease
Meniere's Disease
Primary: Change in Dizziness Handicap Inventory (DHI) Questionnaire Score — 10.25; 49.6 units on a scale
Phase 3 N=504 A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
Pain
Primary: Change From Baseline in Brief Pain Inventory (BPI) Questionnaire Item 6 "Pain Right Now" Score at Week 24 (Per Protocol [PP] Population) — -2.8; -3.2 Units on a scale…
Phase 2 N=10 Oxazyme in Patients With Hyperoxaluria
Hyperoxaluria
Primary: Urinary Oxalate Creatinine Ratio — 68.6; 38.7; 49.6; 34.7 mg/g — p=0.027
Phase 2 N=72 Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
Dry Eye Syndrome · Dry Eye
Primary: Corneal Staining (Inferior Region) in the Worst Eye in the Controlled Adverse Environment (CAE) Model, Which is a Regulated Environmental Setting Aimed at Exacerbating…
Phase 3 N=1,703 A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease — 16.9; 19.1; 16.5; 204.6 Titer
Phase 4 N=92 The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Simple Reaction Time — -30.92; 180.83 seconds
Phase 3 N=325 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Progression Free Survival (PFS) — 92; 125; 82 Days
N/A N=95 SMS Reminder to Assess Adherence
Pulmonary Disease, Chronic Obstructive
Primary: Adherence to Spiriva HandiHaler Over Time — 99.0; 96.2; 99.5; 99.5 Percentage of applications
N/A N=20 Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression
Ocular Comfort
Primary: Final Comfort — 87.6; 87.9 Units on a scale
Phase 2 N=101 TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents
HIV-1
Primary: The Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 89; 0; 5; 14 Patients
Phase 1 N=30 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
Schizophrenia · Bipolar I Disorder
Primary: Maximum Plasma Concentration (Cmax) of Asenapine — 1.84; 3.48; 9.24; 6.75 ng/mL
N/A N=60 Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
Kidney Failure, Chronic
Primary: Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection) — 12.2 weeks
Phase 2 N=40 Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content — 8.38; 7.72; 8.50; 7.29 percentage of liver fat content — p=0.94
Phase 2 N=170 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Melanoma · Neoplasm Metastasis
Primary: Clinical Response — 0; 0; 0; 0 Participants